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Abstract
Background: Obesity is a public health epidemic and an important breast cancer risk factor. The relationship
between interrelated body measurements is complex and most studies fail to account for this complexity. We
identified key aspects of body size which jointly, over the life-course (since adolescence), are associated with
estrogen-receptor-positive (ER+) breast cancer risk.
Methods: Among 109,862 women participating in the California Teachers Study cohort, 3844 were diagnosed with
invasive ER+ breast cancer between 1997–1998 and December 2011. Based on validated self-reported height and
weight at age 18, baseline, and 10-year follow up and waist circumference at 2-year and 10-year follow up, we
identified 16 a priori body-size phenotypes. Multivariable Cox proportional hazards models provided estimates of
hazard rate ratios (HR) and 95% confidence intervals (CI).
Results: Premenopausal breast cancer was influenced by adolescent, but not adult, body size (HR = 0.51, 95% CI 0.
31–0.86 for body mass index (BMI; kg/m2) ≥25 vs <20 at age 18). Among postmenopausal women currently using
hormone therapy, only those with the greatest body size had increased breast cancer risk (HR = 1.36, 95% CI 1.13–1.
64 for height ≥67 inches and adult BMI ≥25 vs height <67). Among postmenopausal women not currently using
hormone therapy, the relationship between body size and risk was complex, with the largest effects of adiposity
among short women. Among short women, those with gluteal adiposity (HR = 2.70, 95% CI 1.77–4.10) and those
who continued to gain weight throughout adulthood (HR = 2.57, 95% CI 1.60–4.12) were at greatest risk, whereas
those who had been overweight/obese since adolescence were not at increased risk (HR = 1.33, 95% CI 0.84–2.10).
Height was associated with a small increased risk, with borderline statistical significance.
Conclusions: Considering absolute body mass in adolescence and at two points in adulthood, dynamic changes in
adiposity over time, and body fat distribution, we identified obesity phenotypes associated with ER+ breast cancer
risk. Our approach more clearly identifies specific risk groups than do analyses that evaluate similar measures
separately. These findings may aid in improving risk prediction models and developing targeted interventions, and
may clarify inconsistent findings across studies.
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Background
One of the most serious public health crises of the last
30 years worldwide has been the rapidly increasing
prevalence of overweight and obese individuals and the
impact of this epidemic on the risk of many cancers and
other chronic diseases. It is well-established that body
size impacts breast cancer risk and that these associa-
tions vary by menopausal status and the use of hormone
therapy (HT) [1–3]. The risk of premenopausal breast
cancer is elevated among tall women and reduced
among obese women [1, 2]. Overall, postmenopausal
women are at greater risk of breast cancer if they are tall
or obese or have substantial adult weight gain or abdom-
inal adiposity [1, 2]. However, these effects are limited to
women who have not used HT [1, 2, 4–7]. Thus, with
the substantial reduction in HT use since the early
2000s, body size may have a greater impact on postmen-
opausal breast cancer risk than in past decades. Both
risk and the mechanisms involved also vary by the hor-
mone receptor status of the tumor, particularly whether
it is estrogen-responsive [3, 8].
Most epidemiologic studies have examined body size
measures as single independent variables or as the joint
effects of two variables. However, the interrelationships
between various body measurements are complex - indi-
vidual measures are often correlated with each other
(e.g., weight and waist circumference) and over time
within an individual. In addition, the associations be-
tween body size and disease risk reflect confounding and
interactions and can vary over the life-course. For ex-
ample, obesity early in life may not only reduce the risk
of premenopausal breast cancer, but continued obesity
throughout life may delay or ameliorate the risk of post-
menopausal breast cancer normally associated with
obesity in later life [4, 9, 10]. Thus, our objective was to
identify key aspects of body size over the life-course
(since adolescence) that are associated with risk of the
most commonly diagnosed breast cancers (i.e., those that
are estrogen-receptor-positive (ER+)), jointly considering
aspects of absolute obesity and stature, changes in adi-
posity over time, and body fat distributions using data
from our large, diverse cohort of women prospectively
followed for more than 10 years.
Methods
The California Teachers Study (CTS) recruited 133,479
active and retired female public school teachers, admin-
istrators, and other professionals in 1995–1996 [11]. At
the time participants joined the cohort (baseline), they
completed a self-administered questionnaire addressing
health and medical history (including menopausal status,
HT use, and body size), lifestyle, and other exposures
and behaviors. The second follow-up questionnaire,
completed in 1997–1998, included self-measured waist
and hip circumferences. The third (2000–2001) updated
menopausal status and HT use and the fourth (2005–
2006) updated menopausal status, HT use, and body size
measures. Response rates to the follow-up question-
naires were 75%, 74%, and 67%, respectively, with 88% of
the active cohort completing one or more follow-up
questionnaires. The CTS was approved by the Institu-
tional Review Boards at the Cancer Prevention Institute
of California, City of Hope National Medical Center, the
University of Southern California, the University of
California at Irvine, and the California Health and Human
Services Agency.
Assessment of body size
Body size measures included in the present analysis were
height, body mass index (BMI; kg/m2), weight change,
and waist-to-height ratio (WHtR). Self-reported height
(in inches) at baseline and at age 18 years were highly
correlated (r = 0.97). Thus, adult height was defined as
height at baseline and if missing, as height at age 18.
BMI was calculated based on self-reported weight
(reported in pounds and converted to kilograms) at age
18 and baseline and adult height as described above
(converted to meters). At the 2-year follow up, women
were provided a standard heavy-weight flexible paper
tape measure (calibrated in inches on both sides with
each side a different color to prevent errors in measure-
ment) and asked participants to measure their waist and
hip circumferences following written, illustrated instruc-
tions. We chose to use WHtR, instead of waist-to-hip ra-
tio, as a measure of abdominal adiposity as the former
has been found to be a better predictor of visceral fat,
while the latter is more strongly correlated with subcuta-
neous fat [12, 13]. Details on the measurement and val-
idation of body measurements have been published
elsewhere [4]. The 10-year follow-up questionnaire in-
cluded questions to update information on weight and
waist circumference. Weight change between age 18 and
baseline and baseline and the 10-year follow-up were
calculated.
We used the following measures to identify lifetime
body size phenotypes: adult height; adolescent BMI (at
age 18 years); BMI at baseline; weight change from age
18 to baseline among women of normal weight (i.e.,
BMI <25) at baseline; and WHtR among women who
were overweight (i.e., BMI 25.0–29.9) or obese (BMI
≥30) at baseline. Based on a priori decisions, we evalu-
ated weight change only among women of normal
weight (BMI <25) under the assumption that among
overweight/obese women the BMI attained was more
important than the amount of weight gain. Similarly,
body fat distribution (WHtR) was evaluated only among
overweight/obese women under the assumption that in
the absence of significant adipose tissue among women
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of normal weight, the site of that tissue had minimal ef-
fect. These assumptions also kept the total number of
phenotypes evaluated at a reasonable number and were
further justified by the very small number of women in
most of the subgroups when additional stratification as
described was examined post hoc. In a second set of
analyses we also incorporated BMI at the 10-year follow
up and weight change from baseline to the 10-year fol-
low up, the latter among women of normal weight at the
10-year follow up.
Follow up for outcomes
The CTS cohort is followed annually for cancer diagno-
ses, changes of address, and deaths. Cancer diagnoses
are determined by linkage with the California Cancer
Registry (CCR), a population-based cancer registry,
which contributes data to the National Cancer Institute
Surveillance, Epidemiology, and End Results program,
and covers the entire state of California. As more than
99% of all cancer diagnoses among California residents
are reported to the CCR [14], cohort members who con-
tinue to reside in California are effectively in active fol-
low up of cancer outcomes. Changes of address are
obtained by annual mailings, notifications from partici-
pants, and record linkages with multiple sources includ-
ing the US Postal Service National Change of Address
database. California and national mortality files are used
to ascertain date of death.
Study population
For the present analysis, we sequentially excluded
women, who at baseline were judged to have invalid data
overall (n = 2); did not live in California (n = 8867); had a
prior history of breast cancer (identified by self-report or
by linkage with the CCR; n = 6212) or whose prior his-
tory of cancer was unknown (n = 139); had a bilateral
mastectomy prior to joining the cohort (n = 11); or were
aged 85 years or older (n = 1980). We began follow up
for the present analysis at the time that the 2-year
follow-up questionnaire was completed (because this
was when abdominal adiposity was assessed). Thus, we
also excluded women who had moved out of California
(n = 1711), died (n = 674), or had been diagnosed with
an invasive or in-situ breast cancer during that time
period (n = 754 and 151, respectively). Also excluded
were 530 women with breast cancer whose ER status
was unknown and 2586 women with unknown meno-
pausal status or HT data at all three assessments (i.e.,
baseline, 5-year, and 10-year follow-up). Thus, the ana-
lysis cohort included 109,862 women among whom
3844 were diagnosed with incident invasive ER+ breast
cancer between completing the 2-year follow up in
1997–1998 and 31 December 2011.
Statistical analysis
Multivariable Cox proportional hazards regression was
used to estimate hazard rate ratios (HR) and 95% confi-
dence intervals (CI) relating breast cancer to measures
of body size over time as a function of menopausal sta-
tus and current HT use. Follow-up time was calculated
as the number of days between completion of the 2-year
follow-up questionnaire (or for those not completing
this second questionnaire, 5 November 1997, the median
date the questionnaire was completed by those who
filled it out) and the first of the following six events:
diagnosis of invasive ER+ breast cancer (n = 3844),
diagnosis of ER-negative (ER-) or in-situ breast cancer
(n = 684 and 1249, respectively), a move outside of
California lasting more than 4 months (n = 9903), death
(n = 11,433), a bilateral mastectomy (n = 15), or the end
of follow up (31 December 2011).
Menopausal status and HT use were collected at base-
line and updated based on data collected at the 5-year
and 10-year follow up. For each woman, these character-
istics were modeled as time-varying covariates with four
levels: premenopausal; postmenopausal, currently using
HT; postmenopausal, not using HT; and unknown.
Perimenopausal women (those with a last menses within
the past six months) were included with the postmeno-
pausal groups based on HT use. The data were repre-
sented as a counting process, with transitions at the
dates of the two follow-up questionnaires (or the median
completion date for non-responders) for each subject
whose status changed. Three subsets of the resulting
counting process data were created for subsequent ana-
lyses (premenopausal; postmenopausal, currently using
HT; and postmenopausal, not using HT) and separate
regression analyses were performed on each subset.
There were 46,847 women who contributed time to the
premenopausal subset, 49,581 to the postmenopausal/
current HT use subset, and 60,278 women to the post-
menopausal/no HT subset.
Age (in days) was used as the time metric in all regres-
sion models, with stratification by age (in years) at base-
line to adjust for calendar effects. Potential confounders
were identified based on prior knowledge and their inde-
pendent associations with breast cancer risk within each
menopausal/HT subset in our cohort. All potential con-
founders were evaluated in each subset separately. For
premenopausal breast cancer, covariates included in the
final analyses were a history of benign breast disease
(yes, no) and family history of breast cancer in a first-
degree relative (yes, no). For postmenopausal breast can-
cer among women currently using HT, the covariates
were nulliparity and among parous women, age at first
full-term pregnancy (in years); history of benign breast
disease; family history of breast cancer in a first-degree
relative; average alcohol consumption in the year prior
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to baseline (non-drinker, <20 g/day, ≥20 g/day); and
neighborhood socioeconomic status (in deciles). For post-
menopausal breast cancer among women not using HTco-
variates were age at menarche (in years from ≤9 to ≥17);
nulliparity and among parous women, age at first full-term
pregnancy; history of benign breast disease; family history
of breast cancer in a first-degree relative; and consumption
of a plant-based diet (factor score [15]). Neither physical
activity nor four other dietary patterns [15] were associated
with risk in any of the menopausal/HT-use groups and
only 5% of the women were smokers at baseline [11], thus,
these factors were not included as potential confounders.
Model selection
For each menopausal/HT subset, our approach for iden-
tifying the lifetime body size phenotypes of importance
proceeded in three steps. First, we examined the effects
of each body size variable separately across a range of
levels, collapsing each variable, when possible, into two
or three categories based on the observed HRs and CIs,
with the goal of maintaining prediction while achieving
the most parsimonious model. Second, we used the cat-
egories identified from step one to create and evaluate a
full model obtained by partitioning the dataset into a set
of disjoint phenotype categories based on the joint con-
sideration of height, adolescent BMI, BMI at baseline,
weight change among those with normal BMI at base-
line, and type of adiposity (abdominal vs gluteal) among
those who were overweight or obese, as described above.
Finally, we repeatedly collapsed categories created in
step two to achieve a final parsimonious model that
maximized prediction. Collapsing of categories was
based on sample size (precision) within each phenotype
and comparisons of between-phenotype differences
using the Wald test.
Women with missing data on the covariates included
in a given subset were omitted from the analyses re-
ported in Tables 3 and 4. Women with missing data on
any of the body size measures needed to define a specific
phenotypic category in a given model were included in a
single “missing” category for that model. As categories
were collapsed, women could reenter the analyses, hence
the number of cases reported in the two tables may not
exactly sum over the collapsed categories. Once we ob-
tained the best fitting model for each menopausal/HT
subset, we further evaluated the effects of later adult
body size using the same procedures and BMI and
weight change data from the 10-year follow up.
Results
At the start of follow up, 46,822 women were premeno-
pausal, 36,977 were postmenopausal and currently using
HT, and 21,788 were postmenopausal and not using HT
(Table 1). Premenopausal women were more likely to be
nulliparous than postmenopausal women. Postmeno-
pausal women currently using HT were younger than
those who were not using HT. Among parous women,
those who were premenopausal were older at the deliv-
ery of their first child (median = 28 years) than were
women who were postmenopausal (median = 25 years).
Premenopausal women were less likely to have had a be-
nign breast biopsy, a family history of breast cancer, con-
sume a plant-based diet, or have more than one
alcoholic drink (of around 20 g) per day. HT users were
of a slightly higher socioeconomic status than non-users.
The most parsimonious version of each of the
variables of interest which, when considered separately,
predicted ER+ breast cancer risk in each of the meno-
pausal/HT groups is shown in Table 2. A more detailed
analysis of these individual body size variables and post-
menopausal breast cancer risk in the CTS has been pub-
lished previously [4]. Adolescent BMI was inversely
related to premenopausal breast cancer (HR = 0.51, 95%
CI 0.31–0.86 for BMI ≥25 vs BMI <20; p trend = 0.006).
Adult height was positively associated with risk of post-
menopausal breast cancer (HR = 1.19, 95% CI 1.05–1.36
among HT users, and HR = 1.20, 95% CI 1.06–1.35
among women not using HT). Breast cancer among
postmenopausal women not using HT was also sig-
nificantly associated with BMI at baseline and at the
10-year follow up and weight change in both early (age
18 years to baseline) and later (baseline to 10-year follow
up) adulthood. The association between risk of breast can-
cer and abdominal (WHtR ≥0.50), as opposed to gluteal
(WHtR <0.50), adiposity approached statistical significance.
For each menopausal/HT group, we evaluated the as-
sociation between ER+ breast cancer risk and the full
spectrum of body size phenotypes (n = 16), defined by
height, adolescent BMI, baseline BMI, weight change be-
tween age 18 years and age on joining the cohort, and
abdominal adiposity (Table 3). Among premenopausal
women, elevated HRs were observed among tall women
who experienced weight gain between age 18 and baseline,
but whose adult BMI remained within the normal range
(HR = 2.02, 95% CI 1.09–3.75) and short women who at
baseline were overweight/obese and who developed ab-
dominal adiposity (HR = 2.47, 95% CI 0.94–6.53), although
the latter estimate was not statistically significant. The lat-
ter estimate also did not significantly differ from that of
similar women with gluteal adiposity (HR = 1.88, 95% CI
0.25–13.94), although both phenotypes were characterized
by a very small number of cases.
Among postmenopausal HT users, taller women who
had become overweight or obese during adulthood were
at increased risk of breast cancer. The difference in the
magnitude of risk for those women with abdominal
(HR = 1.69, 95% CI 1.19–2.39) vs gluteal (HR = 1.41,
95% CI 1.03–1.92) fat distribution was not statistically
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significant (p = 0.32). Among postmenopausal women
not using HT, weight gain since adolescence, among
women maintaining a normal BMI, increased risk
among both short (HR = 1.39, 95% CI 1.02–1.88) and
tall (HR = 1.66, 95% CI 1.24- 2.21) women. Short
women with gluteal adiposity at baseline (HR = 2.75,
95% CI 1.78–4.25) were at greater risk than those
with abdominal adiposity (HR = 1.48, 95% CI 1.10–
2.00) (p = 0.003); the location of body fat among tall
women did not impact risk, although being over-
weight/obese did (HR = 2.09, 95% CI 1.37–3.18 and
HR = 2.04, 95% CI 1.52–2.73 for gluteal and abdom-
inal adiposity, respectively). Among short women who
were overweight/obese in adolescence, those with nor-
mal BMI at baseline were at increased risk (HR =
2.63, 95% CI 1.75–3.95), whereas those who contin-
ued to be overweight/obese with greater abdominal
girth were not (HR = 1.34, 95% CI 0.77–2.32) (p =
0.03).
To obtain the most parsimonious predictive models,
rare phenotypic combinations (i.e., those with <10 cases)
were collapsed into single groups, as were groups with
similar risk estimates, using an iterative process. In pre-
menopausal women, only adolescent (age 18 years) BMI
remained predictive of risk (see Table 2). Final models
for postmenopausal women are presented in Table 4.
Among HT users, relative to short women, tall over-
weight/obese women were at increased risk of breast
cancer (HR = 1.36, 95% CI 1.13–1.64), but tall women of
normal weight were not (HR = 1.11, 95% CI 0.95–1.30).
Among women not using HT and who had maintained a
normal weight throughout life, the effect of height
approached statistical significance (HR = 1.35 95% CI
1.00–1.81). Shorter women who had been overweight/
obese since adolescence were not at increased risk
(HR = 1.33, 95% CI 0.84–2.10) whereas taller women
were (HR = 1.49, 95% CI 1.06–2.10); although these
HRs did not differ statistically. Adult weight gain was also
associated with increased risk (HR = 1.36, 95% CI 1.03–
1.81 among shorter women and HR = 1.77, 95% CI 1.40–
2.25 among taller women). Among shorter women gluteal
adiposity was associated with a greater increase in risk
(HR = 2.70, 95% CI 1.77–4.10) than was abdominal adi-
posity (HR = 1.45, 95% CI 1.10–1.92) (p = 0.003).
Finally, we evaluated whether later adult body size (i.e.,
BMI at the 10-year follow up and weight change be-
tween baseline and the 10-year follow up) modified any
of the risk estimates in Table 4 (data not shown). We
had too few premenopausal women to conduct this add-
itional analysis. Among postmenopausal HT users, no
modification was observed. Among shorter postmeno-
pausal women not using HT who had gained weight be-
tween age 18 years and baseline (HR = 1.36, 95% CI
1.03–1.81 (Table 4)), additional weight gain of 10 1bs or
more later in life was associated with a substantial in-
crease in risk (HR = 2.57, 95% CI 1.60–4.12), whereas
Table 4 Best fitting models describing the association between life-course body size and estrogen-receptor-positive postmenopausal
breast cancer risk, by HT use
Height BMI (age 18 years) BMI (baseline) Weight change (age 18 years to baseline) Adiposity Cases HR 95% CI
Current HT use
Short 887 1.0b
Tall Normal 190 1.11 0.95–1.30
Overweight/obese 130 1.36 1.13–1.64
Not using HT
Short Normal Normal <10 lbs 83 1.0c
≥10 lbs 115 1.36 1.03–1.81
Overweight/obese Abdominal 125 1.45 1.10–1.92
Gluteal 30 2.70 1.77–4.10
Overweight/obese Normal 36 2.57 1.74–3.81
Overweight/obese 24 1.33 0.84–2.10
Tall Normal <10 lbs 95 1.35 1.00–1.81
≥10 lbs 384 1.77 1.40–2.25
Overweight/obese 54 1.49 1.06–2.10
Body size cut-points: height <65, ≥65 (for postmenopausal women not using hormone therapy (HT)) and <67, ≥67 (for postmenopausal women currently using
HT); body mass index (BMI) (age 18 years) <25, ≥25; BMI (baseline) <25, ≥25; adiposity ≥0.50 (abdominal), <0.50 (gluteal). aAdjusted for history of benign breast
disease and family history of breast cancer in a first-degree relative; age was the time metric and the model was stratified by age at baseline. bAdjusted for nulliparity
and age at first full-term pregnancy, history of benign breast disease, family history of breast cancer in a first-degree relative, average alcohol consumption in the year
prior to baseline, and neighborhood socioeconomic status; age was the time metric and the model was stratified by age at baseline. cAdjusted for age at menarche,
nulliparity and age at first full-term pregnancy, history of benign breast disease, family history of breast cancer in a first-degree relative, and consumption of a plant-
based diet; age was the time metric and the model was stratified by age at baseline
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risk was not increased among those who did not gain
the additional weight (HR = 1.23, 95% 0.79– − 1.91).
Later adult body size did not modify any of the other ob-
served associations with postmenopausal breast cancer.
Discussion
Our analysis suggests that the relationships between
body size phenotypes, based on measures from adoles-
cence through adulthood, and ER+ breast cancer are
complex. We observed that the risk of premenopausal
breast cancer was influenced by adolescent, but not
adult, body size, with greater body mass associated with
a reduction in risk. In addition, while becoming over-
weight/obese in adulthood impacted the risk of post-
menopausal breast cancer, having been overweight/obese
over life since adolescence did not. The use of HT sub-
stantially increases breast cancer risk [16, 17]; this risk
was increased further among those with the largest body
stature (i.e., those who were tall and overweight/obese).
Among postmenopausal women not using HT, the re-
lationship between body size and risk was complex, with
the largest effects of adiposity observed among short
women. Among short women, while weight gain during
adulthood resulting in abdominal adiposity increased
risk, gluteal adiposity was significantly more detrimental;
however, among tall women, body fat distribution did not
modify the risk associated with being overweight or obese
in adulthood. Among short women, continued weight gain
throughout adulthood was also associated with a signifi-
cant increase in risk. Height was associated with increased
risk, with borderline statistical significance.
Our findings on the associations between single body-
size measures and breast cancer risk (Table 2) were con-
sistent with the general consensus in the literature [1].
However, our life-course approach also suggests that
among postmenopausal women currently using HT, the
previously observed overall increased risk associated
with greater height may in fact be limited to taller
women who also have greater overall body mass. In
addition, among postmenopausal women not using HT,
the overall increased risk associated with abdominal adi-
posity was not observed when height and adolescent
body mass were taken into account. This finding is con-
sistent with the literature review published by Pischon et
al. [7]. In fact, among short postmenopausal women
who became overweight or obese due to adult weight
gain after age 18 years but prior to baseline, risk
associated with gluteal adiposity was substantially
greater than that due to abdominal adiposity. This
finding is consistent with the recent report by Harding et
al. [18] suggesting that hip circumference may be a better
predictor of postmenopausal breast cancer than waist
circumference.
Apart from single measures assessed at different ages
and reported separately, there is little literature on the
lifetime effects of body size on breast cancer risk. Stud-
ies in France and Mexico have looked at body shape
trajectories from the prepubertal period to age 35 or
40 years based on Sørensen’s pictograms [19, 20]. In the
French study, relative to women reporting the leanest
body shapes throughout life, women who consistently
reported mid-range or the largest body shapes were at re-
duced risk of ER+ progesterone-receptor-positive (PR+)
postmenopausal breast cancer; women reporting greater
body size during adolescence than during adulthood were
at similar risk but the effect estimate was not significantly
significant [20]. The authors concluded that adiposity at
puberty reduced the risk of later-life breast cancer and this
effect was independent of later-life body size [20]. How-
ever, the opposite was observed in the Mexican study:
women consistently reporting mid-range or the largest
body shapes and those reporting a moderate increase in
body shape size over time were at increased risk of post-
menopausal breast cancer [19]. Neither study found statis-
tically significant associations with premenopausal breast
cancer.
In a similar analysis, conducted in the USA, assessing
trajectories from age 5 to 60 years, moderate or marked
increases in body size increased the risk of postmeno-
pausal breast cancer, but there was no increased risk
among those whose body size was relatively stable
throughout life, regardless of their absolute body size [21].
While these findings are not directly comparable to ours,
the increased risk associated with adiposity acquired dur-
ing adulthood in the studies from Mexico (in which less
than 25% of women had ever used HT) and the USA (in
which no heterogeneity by HT use was reported) is gener-
ally consistent with the patterns we observeS in postmen-
opausal women who were not using HT.
Unlike adult-acquired body mass, several previous stud-
ies have found that being overweight/obese over lifetime
(i.e., since adolescence) may not impact the risk of post-
menopausal breast cancer [4, 9, 10, 20] or in some cases,
may even reduce a woman’s risk [20]. Overall our findings
are consistent with this observation. The implication of
these findings for more recent generations, however, is un-
clear as the relative contribution of heredity, overeating,
sedentary behavior, and the altered hormone levels associ-
ated with each, to adolescent obesity may differ in these
older cohorts than in future ones. Despite our overall find-
ings on adolescent obesity, we did observe a significant in-
crease in risk limited to short women who were
overweight/obese in adolescence but of normal adult body
mass. The reason for this exception is not clear and may
be due to misclassification or chance.
Mechanisms related to sex steroid hormones, inflamma-
tion, and glucose/insulin are suggested as the pathways
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most likely to be involved in anthropometric-related car-
cinogenesis [1, 2, 7]. Adult height in women is usually
established by mid-adolescence and is a marker of aggre-
gated fetal and childhood factors promoting linear growth,
including early-life nutrition and environmental exposures,
hormone profiles and the rate of sexual maturation, and
genetics [1, 2] [22]. In premenopausal women the female
sex steroid hormones are produced largely by the ovaries,
whereas in postmenopausal women estrogens are largely
the result of the conversion of adrenal androgens to estro-
gens in adipose tissue. Adolescent obesity is often associ-
ated with earlier menarche and irregular and anovulatory
menstrual cycles, resulting in altered levels of ovarian hor-
mones, sex hormone binding globulin, and insulin-like
growth factor-1 [2, 6, 20]. These alterations in turn may re-
sult in earlier mammary cell differentiation and lifelong re-
duction in mammary cell growth and proliferation
reducing the risk of breast cancer later in life [2, 13, 20].
Weight gain is an indicator of sustained positive energy
balance and, along with adult obesity, affects circulating
hormones, growth factors, insulin, and inflammatory cyto-
kines which together can increase carcinogenesis, decrease
apoptosis, and stimulate low-grade chronic inflammatory
responses [1, 2, 7, 19]. Adult weight gain primarily reflects
the disposition of fat mass with abdominal fat associated
with impaired glucose metabolism, increased insulin re-
sistance, and in postmenopausal women, altered estrogen
synthesis [1, 6, 7, 13, 23, 24]. Abdominal adiposity is more
closely correlated with visceral adipose tissue, which is
more metabolically active, secreting more cytokines and
hormones, than subcutaneous adipose tissue [7, 24]. Glu-
teal adipocytes, on the other hand, are more likely to be
responsive to female sex steroid hormones [25]. Finally,
exogenous HT may obscure the effect of adiposity on
breast cancer risk by artificially increasing the levels of cir-
culating estrogens [6, 23].
Several limitations of the present analysis should be
noted. First, while determined a priori, our approach to
and interpretation of the analysis is somewhat agnostic,
has a certain degree of subjectivity, involves multiple com-
parisons, and for some subgroups is based on small num-
bers of cases. However, we used quantitative methods, i.e.,
the Wald test, to determine whether specific subgroups dif-
fered. While collapsing subgroups based on small numbers
of cases may have masked some associations, this may also
have reduced over-interpretation of erroneous patterns.
Second, we included only 16 body-size phenotypes in
our analysis. Examining additional phenotypes, such as
absolute weight gain among women with who were over-
weight or obese in adulthood, being overweight or obese
over life, or body fat distribution among women of normal
BMI, may be possible in larger consortial datasets.
Third, our focus was on body size over the life-course
but the available data limited us to evaluation at several
specific points in time only, i.e., age 18 years, baseline
(generally reflecting ages 34–46 in premenopausal
women, 52–65 in postmenopausal women using HT,
and 55–72 in postmenopausal women not using HT),
and 10 years after baseline, and the changes between
these points.
Fourth, while data on menopausal status and HT use
were updated, this was only done at 5-year and 10-year
follow up, rather than more often, and thus, has some
built-in imprecision. The largest change in HT use over
the follow-up period, however, was the substantial popu-
lation cessation of HT use following the publicity sur-
rounding the findings of the Women’s Health Initiative
in 2002–2003 [16, 17]. This event fell between our two
follow-up questionnaires, thus, women who quit use as
a result of this event contributed person-time and events
to the current HT group for a few “extra” years as op-
posed to being switched to the “not currently using HT”
group immediately, which functionally precluded an as-
sumption of instantaneous risk reduction. Relatedly,
some misclassification may have been introduced into
the analysis of adult (baseline) BMI and WHtR in
women who were premenopausal at baseline but post-
menopausal at the 5-year follow up. They would have
contributed person-time to one of the postmenopausal
subgroups between the 5-year and 10-year follow up,
but unlike women who were postmenopausal at baseline
or became postmenopausal after the 5-year follow up,
their adult BMI and WHtR data would have reflected a
premenopausal assessment rather than a postmeno-
pausal one during the 5 years of the follow-up period.
However, these women accounted for only 10% and 15%
of those contributing to the analyses of postmenopausal/
current HT and postmenopausal/not using HT groups,
respectively. After the 10-year reassessment of both
menopausal status and body size, this would not have
been a concern.
Fifth, the anthropometric data used in the present ana-
lysis were self-reported, which can result in measure-
ment error due to lack of knowledge, most notably for
weight at age 18 years, or desire to report a socially
more normative value. However, our validation study
suggested excellent reproducibility and validity, minimiz-
ing such concerns [4]. Last, we did not include other
body size measures, such as weight cycling, which in
one study was found to be associated with the greatest
risk of breast cancer [5].
Notable strengths of this analysis include the unique
conceptual approach taken to assessing the effects of
body size over the life-course and the conduct of these
analyses in a large cohort of women who had detailed
data on anthropometry and breast cancer outcomes over
the course of more than 15 years. We included both dy-
namic (e.g., weight change) and static measures (e.g.,
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BMI) of body size, of which the former may better re-
flect age-related metabolic changes, while the latter re-
flects the effects of absolute size [6]. In addition, when
assessing abdominal (android) versus gluteal (gynoid)
obesity, we used the ratio of waist circumference to
height rather than the more common waist circumfer-
ence or waist-to-hip ratio, as the former is a better pre-
dictor of visceral fat [12].
Conclusions
Taking into account absolute body mass, changes in adi-
posity over time, and body fat distribution, we identified
lifetime (since adolescence) obesity phenotypes which
were associated with breast cancer risk in our large co-
hort. These findings may aid in improving risk predic-
tion models and developing targeted interventions, and
may clarify inconsistent findings across studies to the ex-
tent that the composition of the study populations differ
in regards to important anthropometric indicators. To
the extent that equally detailed anthropometry is avail-
able in other studies, similar analyses conducted in large
consortial datasets, such as the Cohort Consortium or
the Harvard Diet Pooling Project, are needed to confirm
our findings and improve statistical power for evaluating
effect modification across rare phenotypes.
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